Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE.

• Harrow (NasdaqGM:HROW) announced the launch of BYOOVIZ in the retinal biosimilar market, adding a new product to its ophthalmology lineup.

• The company reported expanded formulary coverage for VEVYE, increasing potential patient access to its dry eye disease treatment.

• Harrow acquired TYRVAYA, further building out its portfolio focused on dry eye disease.

This cluster of product moves and acquisitions around eye care is part of a wider push across healthcare, and investors who follow Harrow may also want to review other companies linked to this theme through 43 healthcare AI stocks .

Harrow focuses on prescription eye care treatments in the US, so the addition of new retinal and dry eye products deepens its presence across several ophthalmic niches. For you as an investor, this means the business is concentrating on areas where eye specialists already recognize its brand and product lineup.

2 things going right for Harrow that this headline doesn't cover.

Harrow's product moves test its portfolio-expansion Narrative

The investment story around Harrow centres on a broader ophthalmic portfolio and stronger coding and access routes that spread revenue across more products. This launch and acquisition activity speaks directly to that Narrative because it links new therapies to the same commercial engine and eye-care specialist relationships.

"Improved patient access, partnerships, and integration of new innovative products strengthen competitive positioning and enable outsized earnings growth…"

Read the full Harrow narrative to see the case behind these numbers

For that thesis, BYOOVIZ and TYRVAYA matter because they add retinal and dry eye categories onto Harrow's existing commercial infrastructure rather than building something separate. Expanded VEVYE formulary coverage also leans into the Narrative's focus on access programs as a key driver, especially as Harrow competes with players like AbbVie and Novartis in specialist eye care.

At the same time, the second quarter 2026 net loss and reiterated 2026 revenue guidance highlight the execution risk already flagged in the Narrative. Integrating BYOOVIZ and TYRVAYA and turning broader access for VEVYE into sustained prescription volumes will be an important test of operating leverage and product-dependence concerns.

For you as an investor, this news only really matters in the context of whether you accept Harrow's broader Narrative about a diversified, access-driven ophthalmic portfolio or not.To ensure you're always in the loop on how the latest news impacts the investment narrative for Harrow, head to the community page for Harrow to never miss an update on the top community narratives.